Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 2/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MPO | P05164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4164764 | 0.87 | MEN1 (0.31) | MEN1KMT2ASMN1; SMN2MPO | |
| SCHEMBL4161956 | 0.85 | MPO (0.31) | MEN1KMT2ASMN1; SMN2MPO | |
| SCHEMBL4171206 | 0.82 | MEN1 (0.35) | L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4171295 | 0.82 | MEN1 (0.35) | L3MBTL1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4172815 | 0.80 | KDM4E (0.38) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4161947 | 0.79 | PKM (0.36) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4171943 | 0.76 | MAPT (0.31) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4169700 | 0.75 | MEN1 (0.36) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1027343 | 0.75 | MPO (0.33) | L3MBTL1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2890776 | 0.74 | MEN1 (0.31) | MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048112-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| US-20090048112-A1 | Novel Herbicides | SYNGENTA LIMITED (GB) | 2009-02-19 | — | — | US | disclosed |
| EP-1885720-A2 | 4-(THIAZOL-2-YLTHIOALKYL)-PYRAZOLES AND THEIR USE AS HERBICIDES | Syngenta Limited (GB) | 2008-02-13 | — | — | EP | disclosed |
| WO-2006123088-A2 | 4- (THIAZOL-2-YLTHIOALKYL) -PYRAZOLES AND THEIR USE AS HERBICIDES | SYNGENTA LIMITED (GB) | 2006-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048112-A1 | Novel Herbicides | HAX1, MTX1, CYP4X1 | L3MBTL1 927/4885MAPT 4688/4885MEN1 1520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.